MANTLE CELL LYMPHOMA
Clinical trials for MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for elderly lymphoma patients: targeted pill without chemo
Disease control Not yet recruitingThis study tests a daily pill called pirtobrutinib in elderly patients (70+) with mantle cell lymphoma who are too frail for standard chemotherapy. The drug targets a specific protein to control the cancer. Patients will take the pill until the disease worsens or side effects bec…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
Immune cell army targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) to help the body fight the…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New pill combo could boost CAR-T power against tough lymphoma
Disease control Not yet recruitingThis study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve outcomes for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults whose cancer is measurable and who …
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New hope for lymphoma patients after CAR t fails: glofitamab trial launches
Disease control Not yet recruitingThis study tests a drug called glofitamab in 41 people with mantle cell lymphoma whose cancer did not respond or came back after CAR T-cell therapy. The goal is to see if glofitamab can shrink or eliminate tumors. Participants receive the drug and are monitored for response and s…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New combo therapy aims to improve First-Line treatment for mantle cell lymphoma
Disease control Not yet recruitingThis study tests a combination of chemotherapy (bendamustine) and targeted therapy (orelabrutinib plus an anti-CD20 antibody) as a first treatment for people with mantle cell lymphoma who are older or cannot have a stem cell transplant. The goal is to see if this approach helps c…
Matched conditions: MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 05, 2026 11:54 UTC